Bristol Myers Squibb Partners with BioArctic in $100M Alzheimer’s Deal

Partnership:
Bristol Myers Squibb has entered into a collaboration with BioArctic, the original developer of Leqembi, to further develop treatments for Alzheimer's disease15.

Financial Terms:
Bristol Myers Squibb will pay $100 million upfront as part of the agreement1.

Leqembi Background:
Leqembi (lecanemab) is a drug that has been granted full approval by the FDA for treating patients in the early stages of Alzheimer's disease. It works by targeting amyloid plaques in the brain, which are a hallmark of Alzheimer's disease23.

BioArctic's Role:
BioArctic invented Leqembi and has developed the BrainTransporter technology, which aims to improve drug delivery across the blood-brain barrier. This technology will be utilized in the collaboration5.

Future Directions:
The partnership aims to advance and optimize the development of anti-amyloid-beta antibody treatments, leveraging BioArctic's BrainTransporter technology to potentially improve efficacy and reduce side effects5.

Sources:

1. https://endpts.com/bristol-myers-pays-100m-upfront-to-collaborate-with-leqembi-originator-in-alzheimers/

2. https://medicine.washu.edu/news/what-to-know-about-the-new-alzheimers-drug-leqembi/

3. https://investors.biogen.com/news-releases/news-release-details/leqembir-lecanemab-authorized-early-alzheimers-disease-great

5. https://www.bioarctic.com/en/bioarctic-announces-global-license-agreement-with-bristol-myers-squibb-for-bioarctics-pyroglutamate-amyloid-beta-antibody-program/